Comparison of D 2 dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects

International Journal of Neuropsychopharmacology

Volumn 14, Issue 10, 2011, Pages 1357-1366

  Nord, Magdalena ^a   Nyberg, Svante ^b   Brogren, Jacob ^b   Jucaite, Aurelija ^b   Halldin, Christer ^a   Farde, Lars ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA   (United Kingdom)

Author keywords

D2 dopamine receptor; PET; quetiapine

Indexed keywords

CARBON 11; DOPAMINE 2 RECEPTOR; DRUG METABOLITE; NORQUETIAPINE; QUETIAPINE; RACLOPRIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED RELEASE FORMULATION; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG FORMULATION; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACODYNAMICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA; BINDING, COMPETITIVE; BIOTRANSFORMATION; CARBON RADIOISOTOPES; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DIBENZOTHIAZEPINES; DRUG ADMINISTRATION SCHEDULE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; SWEDEN; YOUNG ADULT;

EID: 80054998061     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711000514     Document Type: Article

References (35)

1. Baldwin CM, Scott LJ (2009). Quetiapine extended release : in schizophrenia. CNS Drugs 23, 261-269.
2. Calabrese JR, Keck PE, Macfadden W, Minkwitz M, et al. (2005). A randomized, double-blind, placebo controlled trial of quetiapine in the treatment of bipolar I or II depression. American Journal of Psychiatry 162, 1351-1360. (Pubitemid 40905587)
3. Cohen LJ (1994). Risperidone. Pharmacotherapy 14, 253-265. (Pubitemid 24161030)
4. Datto C, Berggren L, Patel JB, Eriksson H (2009). Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation : A randomized, double-blind, crossover study in healthy adult subjects. Clinical Therapeutics 31, 492-502.
5. Davis PC, Bravo O, Gehrke M, Azumaya CT (2010). Development and validation of an LC-MS/MS method for the determination of quetiapine and four related metabolites in human plasma. Journal of Pharmaceutical and Biomedical Analysis 51, 1113-1119.
6. DeVane CL, Nemeroff CB (2001). Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clinical Pharmacokinetics 40, 509-522.
7. Farde L, Hall H, Pauli S, Halldin C (1995). Variability in D2-dopamine receptor density and affinity: a PET study with [11C]raclopride in man. Synapse 20, 200-208.
8. Farde L, Nordström AL, Wiesel FA, Pauli S, et al. (1992 Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Archives of General Psychiatry 49, 538-544.
9. Figueroa C, Brecher M, Hamer-Maansson JE, Winter H (2009). Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Progress in Neuropsychopharmacology and Biological Psychiatry 33, 199-204.
10. Gefvert O, BergströmM, La?ngström B, Lundberg T, et al. (1998). Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berlin) 135, 119-126. (Pubitemid 28055494)
11. Hasselstrom J, Linnet K (2004). Quetiapine serum concentrations in psychiatric patients : The influence of comedication. Therapeutic Drug Monitoring 26, 486-491. (Pubitemid 39314315)
12. Innis RB, Cunningham VJ, Delforge J, Fujita M, et al. (2007). Consensus nomenclature for in vivo imaging of reversibly binding radioligands. Journal of Cerebral Blood Flow and Metabolism 27, 1533-1539. (Pubitemid 47301451)
13. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, et al. (2008). N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 33, 2303-2312.
14. Kane JM (1989). The current status of neuroleptic therapy. Journal of Clinical Psychiatry 50, 322-328. (Pubitemid 19239054)
15. Kapur S, Zipursky R, Jones C, Remington G, et al. (2000a). Relationship between dopamine D2 occupancy, clinical response, and side effects : A double-blind PET study of first-episode schizophrenia. American Journal of Psychiatry 157, 514-520. (Pubitemid 30191189)
16. Kapur S, Zipursky R, Jones C, Shammi CS, et al. (2000b). A positron emission tomography study of quetiapine in schizophrenia : A preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Archives of General Psychiatry 57, 553-559. (Pubitemid 30349435)
17. Karlsson P, Farde L, Halldin C, Sedvall G, et al. (1995). Oral administration of NNC 756 - a placebo controlled PET study of D1-dopamine receptor occupancy and pharmacodynamics in man. PsychopharmacologyBerlin) 119, 1-8.
18. Lammertsma AA, Hume SP (1996). Simplified reference tissue model for PET receptor studies. Neuroimage 4, 153-158.
19. Langer O, Nagren K, Dolle F, Lundkvist C, et al. (1999). Precursor synthesis and radiolabelling of the dopamine D2 receptor ligand [11C]raclopride from [11C]methyl triflate. Journal of Labelled Compounds and Radiopharmaceuticals 42, 1183-1193.
20. Mamo DC, Uchida H, Vitcu I, Barsoum P, et al. (2008). Quetiapine extended-release vs. immediate-release formulation: a positron emission tomography study. Journal of Clinical Psychiatry 69, 81-86. (Pubitemid 351282000)
21. Nemeroff CB, Kinkead B, Goldstein J. (2002). Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. Journal of Clinical Psychiatry 63 (SUPPL. 13), 5-11. (Pubitemid 35471364)
22. Nord M, Farde L (2010). Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neuroscience & Therapeutics 17, 97-103.
23. Nordström AL, Farde L, Nyberg S, Karlsson P, et al. (1995). D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration : A PET study of schizophrenic patients. American Journal of Psychiatry 152, 1444-1449.
24. NordströmAL, Nyberg S, Olsson H, Farde L (1998). Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients. Archives of General Psychiatry 55, 283-284.
25. Nyberg S, Dencker SJ, Malm U, Dahl ML, et al. (1998). D2- and 5-HT2 receptor occupancy in high-dose neuroleptictreated patients. International Journal of Neuropsychopharmacology 1, 95-101. (Pubitemid 128538369)
26. Nyberg S, Eriksson B, Oxenstierna G, Halldin C, et al. (1999). Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. American Journal of Psychiatry 156, 869-875. (Pubitemid 29260341)
27. Nyberg S, Farde L, Eriksson L, Halldin C, et al. (1993). 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology (Berlin) 110, 265-272.
28. Nyberg S, Farde L, Halldin C (1996). Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy. A PET study in haloperidol-treated patients. Psychiatry Research 67 163-171.
29. Roland PE, Graufelds CJ, Wa?hlin J, Ingelman L, et al. (1994). Human brain atlas for high-resolution functional and anatomical mapping. Human Brain Mapping 1, 173-184.
30. Seroquel1 Prescribing Information (2010a). Quetiapine fumarate (http://www1.astrazeneca-us.com/pi/Seroquel.pdf). Accessed November 2010.
31. Seroquel1 XR Prescribing Information (2010b). Quetiapine fumarate (http://www1.astrazeneca-us.com/pi/ seroquelxr.pdf). Accessed November 2010.
32. Tauscher J, Jones C, Remington G, Zipursky RB, et al. (2002). Significant dissociation of brain and plasma kinetics with antipsychotics. Molecular Psychiatry 7, 317-321. (Pubitemid 34280640)
33. Tauscher-Wisniewski S, Kapur S, Tauscher J, Jones C, et al. (2002). Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. Journal of Clinical Psychiatry 63, 992-997. (Pubitemid 35388057)
34. Varrone A, Sjöholm N, Eriksson L, Gulyás B, et al. (2009). Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. European Journal of Nuclear Medicine and Molecular Imaging 36, 1639-1650.
35. Weiden PJ (2007). EPS profiles: the atypical antipsychotics are not all the same. Journal of Psychiatric Practice 13, 13-24. (Pubitemid 46148428)